Loading...
Myomo Q1 2025 Earnings Report
Myomo reported its financial and operating results for the first quarter of 2025, with significant revenue growth and an increase in patient pipeline.
Key Takeaways
Myomo, Inc. reported strong financial results for the first quarter of 2025, with revenue increasing by 162% to $9.8 million. The company also saw a record number of new candidates added to its patient pipeline, despite challenges from Medicare Advantage plans and social media algorithm changes.
Revenue for Q1 2025 was $9.8 million, a 162% increase compared to Q1 2024.
The company reported a net loss of $3.465 million, or $0.08 per share, for Q1 2025.
A record 700 new candidates were added to the patient pipeline, increasing the total pipeline to 1,482 candidates.
Gross margin improved to 67.2% in Q1 2025, up 600 basis points from the previous year.
Revenue by Segment
Forward Guidance
Myomo expects second quarter revenue to be between $9.0 million and $9.5 million, and full-year 2025 revenue to be in the range of $50 million to $53 million, representing a significant increase over 2024.
Positive Outlook
- Expectation of revenue growth acceleration in the second half of 2025.
- Continued focus on patients with insurers who have previously reimbursed for MyoPro.
- Ability to scale the business to return to positive cash flow from operations on a quarterly basis by Q4 2025.
- Ongoing efforts to obtain and maintain strategic collaborations.
- Commitment to improving existing products and developing new ones.
Challenges Ahead
- Temporary lead generation challenges experienced early in the first quarter.
- Continued utilization management by Medicare Advantage plans impacting authorizations and orders.
- Changes to social media algorithms disrupting lead flow and increasing cost per pipeline add.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...